Chronic Experimental Diabetes Accelerates Urinary Elimination of Deprenyl and its Metabolites
Ernest Adeghate*, 1, Péter Sótonyi, Jr2, Huba Kalász3, §
Identifiers and Pagination:Year: 2008
First Page: 1
Last Page: 5
Publisher Id: TOMCJ-2-1
Article History:Received Date: 3/12/2007
Revision Received Date: 26/12/2007
Acceptance Date: 27/12/2007
Electronic publication date: 10/1/2008
Collection year: 2008
open-access license: This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.5/), which permits unrestrictive use, distribution, and reproduction in any medium, provided the original work is properly cited.
Many diabetic patients take several medications to treat diabetes-associated complications and other ailments. The mode of elimination of these drugs and their metabolites are poorly understood. The elimination of deprenyl, a MAO-B inhibitor, used for the treatment of the early stage of Parkinson’s disease and senile dementia was investigated using thin layer chromatography.
Male Wistar rats (180-200 g) were rendered diabetic by streptozotocin (STZ) treatment (60 mg/kg, i.v.). Rats having at least three times higher plasma glucose level than the normal were considered diabetic. Rats were treated with a single oral dose of 5 mg/kg 14C-(methyl)-labeled (-)-deprenyl, 98 (Ci/mg. Diabetic rats excreted the majority of urinary radioactivity in 8 hours, while control rats did it in 16 hours. The approximate ratio of major metabolites as determined using thin-layer chromatography did not change. In conclusion, diabetic rats excreted radiolabelled-deprenyl more rapidly compared to control animals. Increased elimination of deprenyl should be taken into account in the management of patients suffering from diabetes.